Regenafil Versus Demineralized Freeze Dried Bone Allograft (DFDBA) for Periodontal Defects
Periodontal Diseases
About this trial
This is an interventional prevention trial for Periodontal Diseases focused on measuring Periodontal Treatment of Intraosseous Vertical Defects
Eligibility Criteria
Inclusion Criteria: Provide written informed consent prior to their participation. Be an adult age 18 and older. Have at least a 4 mm open vertical osseous defect depth on one tooth, visible on a radiograph and with a probing depth ≥ 5 mm. Have osseous defects that are either wide 3-wall, or combination defects. Exclusion Criteria: Have debilitating systemic diseases, or diseases that affect the periodontium. Have a known allergy to any of the materials that will be used in the study: non-steroidal anti-inflammatory drugs (NSAIDs) chlorhexidine digluconate doxycycline gelatin Need prophylactic antibiotics. Have a vertical osseous defect that is related to a furcation area. Smoke more than 1 pack per day. Have endodontically treated teeth or endodontic lesions at study sites. Have 1-wall defects. Have poor oral hygiene. Have anterior fillings (Note: if a subject presents with anterior fillings, it will be at the discretion of the principal investigator as to whether they should be accepted into the study.) Be pregnant as evidenced by a positive urine pregnancy test taken at both the screening and baseline visits.
Sites / Locations
- Indiana University School of Dentistry
- University of Louisville School of Dentistry
Arms of the Study
Arm 1
Arm 2
Experimental
Active Comparator
Regenafil graft
DFDBA
Regenafil
Demineralized Freeze Dried Bone Allograft